Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
Want to see AU:IBX full AI Analyst Report?
IBX Stock Chart & Stats
AU$0.03
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.03
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume347.18K
Average Volume (3M)16.05M
Market Cap
AU$7.85M
Enterprise ValueAU$4.25M
Total Cash (Recent Filing)AU$1.85M
Total Debt (Recent Filing)AU$2.56M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding490,590,240
10 Day Avg. Volume7,347,790
30 Day Avg. Volume16,053,124
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary TechnologyOwning the MagSense magnetic-nanoparticle imaging platform is a durable competitive asset: it creates technical differentiation and potential patents, supports multiple diagnostic applications beyond a single test, and can provide high switching costs and licensing opportunities if clinical and regulatory milestones are achieved.
High Gross Margin PotentialA reported ~85% gross margin in 2024 indicates attractive unit economics when product sales occur. If the company converts clinical validation into commercial sales, these margins can sustainably fund R&D and commercial expansion, supporting long-term profitability leverage as volumes scale.
Improving Cash Outflow TrendThe reduction in free cash outflow in 2025 signals improving operational discipline or cost structures. A sustained downward trend in cash burn increases runway and reduces near-term financing risk, improving the firm's ability to reach key clinical or regulatory inflection points without immediate dilution.
Bears Say
Revenue CollapseZero reported revenue in 2025 shows the business currently lacks commercial product traction. Without stable sales, the company must rely on external financing to fund operations and validation activities, delaying self-sustaining growth and increasing execution risk over the next several months.
Negative Equity / Solvency StressNegative shareholders' equity since 2023 signals persistent losses that have eroded the capital base. This structural balance-sheet weakness restricts borrowing capacity, raises counterparty concerns, and constrains strategic flexibility, making the company dependent on timely external capital to operate.
Persistent Cash BurnConsistent negative operating and free cash flows, with ~4.0M cash burn in 2025, create an ongoing funding requirement. Persistent outflows combined with modest debt levels mean the firm faces continual refinancing and dilution risk, limiting its ability to invest aggressively in commercialization or larger trials.
Imagion Biosystems Ltd. News
IBX FAQ
What was Imagion Biosystems Ltd.’s price range in the past 12 months?
Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Imagion Biosystems Ltd.’s market cap?
Imagion Biosystems Ltd.’s market cap is AU$7.85M.
When is Imagion Biosystems Ltd.’s upcoming earnings report date?
Imagion Biosystems Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 80 days.
How were Imagion Biosystems Ltd.’s earnings last quarter?
Imagion Biosystems Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Imagion Biosystems Ltd. overvalued?
According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued.
Does Imagion Biosystems Ltd. pay dividends?
Imagion Biosystems Ltd. does not currently pay dividends.
What is Imagion Biosystems Ltd.’s EPS estimate?
Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imagion Biosystems Ltd. have?
Imagion Biosystems Ltd. has 490,590,240 shares outstanding.
What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?
Imagion Biosystems Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?
Currently, no hedge funds are holding shares in AU:IBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imagion Biosystems Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.50%
12-Months-Change
Fundamentals
Return on Equity
142.99%
Trailing 12-Months
Asset Growth
-27.09%
Trailing 12-Months
Company Description
Imagion Biosystems Ltd.
Imagion Biosystems Limited specializes in developing advanced medical imaging solutions. Their core technology, superparamagnetic relaxometry, is employed for detecting diseases, particularly cancer, and for tracking the efficacy of treatments. The company's work spans nanotechnology, biotechnology, and cancer diagnostics, with a primary focus on superparamagnetic relaxometry. Among its key innovations are MagSense, which is in Phase I clinical trials for HER2 breast cancer therapy, and PrecisionMRX, an iron oxide nanoparticle designed for cancer detection. Imagion Biosystems also maintains a collaborative research program with Patrys Limited, aiming to integrate their technologies to enhance brain tumor imaging and diagnosis. Furthermore, they have a joint development agreement with Global Cancer Technology, Inc. to advance GCT's novel nanoscintillator technology for breast cancer treatment. The company was founded in 2016 and is headquartered in San Diego, California.
Technical Analysis
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---